Accéder au contenu
Merck

Porcine iPSC Generation: Testing Different Protocols to a Successful Application.

Methods in molecular biology (Clifton, N.J.) (2021-12-01)
Oriol Iborra-Egea, Daina Martínez-Falguera, Santiago Roura, Antoni Bayes-Genis, Ángel Raya, Carolina Gálvez-Montón
RÉSUMÉ

Stem cell therapy has an unparalleled potential to treat blood cancers, cardiovascular diseases and neurodegenerative conditions, among others. However, stem cell therapeutics must overcome multiple requirements before reaching clinical trials, including large animal safety and efficacy studies. In cardiovascular diseases swine models are the most widely adopted due to its great translational potential to humans. In this chapter, we will describe several protocols to induce iPSC dedifferentiation in swine fibroblasts, as well as conditioning treatments that may help in the reprogramming process.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
CHIR99021, ≥98% (HPLC)
Sigma-Aldrich
BCFbh, FGF-Basic, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
Puromycine dihydrochloride, Ready Made Solution, from Streptomyces alboniger, 10 mg/mL in H2O, suitable for cell culture
Sigma-Aldrich
Protéine LIF de souris recombinante ESGRO®, ESGRO Leukemia Inhibitory Factor (LIF) supplement for mouse ES cell culture. Each vial contains 10^7 units/ml.
Sigma-Aldrich
SB 431542 hydrate, ≥98% (HPLC), powder
Roche
Sérum albumine bovine, blood typing: suitable, Endonuclease, Exonuclease, Rnases, Proteinases free
Sigma-Aldrich
5-Aza-2′-deoxycytidine, ≥97%
Sigma-Aldrich
MEK1/2 Inhibitor III, The MEK1/2 Inhibitor III, also referenced under CAS 391210-10-9, controls the biological activity of MEK1/2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.